pan-Canadian Oncology Drug Review
Economic Guidance Report Template

[Insert Report Name and Report Number]

[Insert Month and Year]

DISCLAIMER

[Insert text here]

FUNDING

[Insert text here]

RECORD OF UPDATES

Update	Version	Reported on pCODR Website
Original	July 2011	July 21, 2011
Version 2	December 2015	December 11, 2015

INQUIRIES

Inquiries and correspondence about the pan-Canadian Oncology Drug Review (pCODR) should be directed to:

pan-Canadian Oncology Drug Review
154 University Avenue, Suite 300
Toronto, ON
M5H 3Y9

Telephone: 613-226-2553
Toll Free: 1-866-988-1444
Fax: 1-866-662-1778
Email: requests@cadth.ca
Website: www.cadth.ca/pcodr

TABLE OF CONTENTS

1 ECONOMIC GUIDANCE IN BRIEF

This section summarizes the pCODR Economic Guidance Panel's (EGP's) evaluation of the economic evidence in plain language. This section will be publicly posted. Structured wording is provided in the template as a guide to ensure that plain language is used and to provide consistency across reports for lay public readers. This wording should be considered a guide and may be modified on a case-by-case basis. The instructions below are intended to provide examples of the important material to summarize in this section. They are not a comprehensive list of what should be included.

1.1 Submitted Economic Evaluation

The economic analysis **submitted to pCODR by [manufacturer/tumour group]** compared [drug x] to [comparator y] for patients with [indication].

Table [x]. Submitted Economic Model

Funding Request/Patient Population Modelled	
Type of Analysis	
Type of Model	
Comparator	
Year of costs	
Time Horizon	
Perspective	
Cost of [drug x]	
Cost of [comparator y]	
Model Structure	
Key Data Sources	

1.2 Clinical Considerations

According to the pCODR Clinical Guidance Panel (CGP), this comparison is [appropriate/not appropriate].

- Relevant issues identified included:
    - [Insert text here]

Summary of patient advocacy group input relevant to the economic analysis
Patients considered [factor1, factor2, factor3].

Summary of Provincial Advisory Group (PAG) input relevant to the economic analysis
PAG considered the following factors (enablers or barriers) important to consider if implementing a funding recommendation for [drug x] which are relevant to the economic analysis: ([factor1, factor2, factor3].

1.3 Submitted and EGP Reanalysis Estimates

Table [x]. Submitted and EGP Estimates

Estimates	Submitted	EGP Reanalysis
ICER estimate ($/QALY), range/point		
ΔE (QALY), range/point		
ΔE (LY), range/point		
ΔC ($), range/point		

The main assumptions and limitations with the submitted economic evaluation were:

[Insert text here]

1.4 Detailed Highlights of the EGP Reanalysis

The EGP made the following changes to the submitted economic model:

- [Insert text here]

Table [x]: Detailed Description of EGP Reanalysis

	ΔC	ΔE QALYs	ΔE LYs	ICUR (QALY)	Δ from baseline submitted ICER
Baseline (Submitter's best case)					--

1.5 Evaluation of Submitted Budget Impact Analysis

The factors that most influence the budget impact analysis include [factor1, factor2, factor3].

Key limitations of the BIA model include [factor1, factor2, factor3].

1.6 Conclusions

The EGP's best estimate of ΔC and ΔE for [drug x] when compared to [comparator y] is:

- [Insert text here]
- The extra cost of [drug x] is between [ΔC] and [ΔC].
- The extra clinical effect of [drug x] is between [ΔE] and [ΔE] (ΔE).

Overall conclusions of the submitted model:

[Insert text here]

2 DETAILED TECHNICAL REPORT

This section outlines the full technical details of the EGP's evaluation of the economic evidence. It will be provided to the pCODR Expert Review Committee (pERC) but will not be publicly posted. An Executive Summary is not required as similar summary information should be included in Section 1 (Guidance in Brief).

2.1 Description of Model Inputs in the Submitted Model

[Insert text here]

Table [x]. Description of Model Inputs in Submitted Model.

Model Input	Base Case Value	Data Source	Direct or calculated variable (If calculated, describe how)	EGP Comments
TRIAL CHARACTERISTICS				
CLINICAL EFFECTIVENESS				
HEALTH-RELATED UTILITIES				
RESOURCE USE AND COSTS				
OTHER - DETAILS				

2.2 Description of Submitted Results

[Insert text here]

Table [x]. Description of Submitted Results

Description	Costs	ΔC	Clinical Effect (LYs, QALYs)	ΔE	ICER/ICUR
Main Analysis (i.e. Base Case Analysis)					
Cost-effectiveness Analysis					
Drug x					
Comparator y					
Cost-utility Analysis					
Drug x					
Comparator y					
Modifications to Main Analysis (i.e. Sensitivity Analyses, Scenario Analyses)					

Table [x]. Summary of QALY gain and costs

QALY gain *(indicate if discounted or undiscounted)*				
	QALY Drug X	QALY Comparator Y	Δ	% (Δ of Total)
Total				
By Health State				
By Data Source				
Costs *(indicate if discounted or undiscounted)*				
Category	Cost Drug X	Cost Comparator Y	Δ	% (Δ of Total)

2.3 Limitations & EGP Reanalysis of Submitted Model

[Insert text here]

Table [x]. Assumptions and Limitations in the Submitted Economic Model.

Category	Key Assumption/Limitation in Submitted Model	Practical Implications
Overall Conclusion on Assumptions and Limitations in Submitted Model:		

Detailed Description of the EGP Reanalysis

[Insert text here]

The EGP made the following changes to the economic model:

- [Insert text here]

Table [x]. EGP Reanalysis Estimates

One-way and multi-way sensitivity analyses					
Description of Reanalysis	ΔC	ΔE QALYs	ΔE LYs	ICER (QALY)	Δ from baseline submitted ICER
EGP's Reanalysis for the Best Case Estimate					
Description of Reanalysis	ΔC	ΔE QALYs	ΔE LYs	ICER (QALY)	Δ from baseline submitted ICER

2.4 Comparison with Published Economic Models

[Insert text here]

2.5 Evaluation of Submitted Budget Impact Analysis

[Insert text here]

Table [x]. Submitted Budget Impact Analysis

Perspective	
Patient population	
Year of costs	
Time Horizon	
Key Inputs/Assumptions	
Market Share: reference scenario	
Market Share: treatment-funded scenario	
Comparator	
Cost drivers	
Other	

Table [x]. Results of Budget Impact Analysis

	Reference Scenario	Treatment-funded Scenario	Incremental Difference
Budget Impact			
Year 1			
Year 2			
Year 3			
3 Year Budgetary Impact			

The factors that most influence the budget impact analysis include [factor1, factor2, factor3].

Key limitations of the BIA model include [factor1, factor2, factor3].

2.6 Conclusions *(Identical to 1.6 Conclusions)*

The EGP's best estimate of ΔC and ΔE for [drug x] when compared to [comparator y] is:

- [Insert text here]
- The extra cost of [drug x] is between [ΔC] and [ΔC].
- The extra clinical effect of [drug x] is between [ΔE] and [ΔE] (ΔE).

Overall conclusions of the submitted model:

[Insert text here]

3 ABOUT THIS DOCUMENT

This Economic Guidance Report was prepared by the pCODR Economic Guidance Panel and supported by the pCODR [Tumour Group] Clinical Guidance Panel and the pCODR Methods Team. This document is intended to advise the pCODR Expert Review Committee (pERC) regarding resource implications and the cost-effectiveness of [drug name and indication]. A full assessment of the clinical evidence of [drug name and indication] is beyond the scope of this report and is addressed by the relevant pCODR Clinical Guidance Report. Details of the pCODR review process can be found on the pCODR website (www.cadth.ca/pcodr).

The Economic Guidance Panel is comprised of economists selected from a pool of panel members established by the pCODR Secretariat. The panel members were selected by the pCODR secretariat, as outlined in the pCODR Nomination/Application Information Package and the Economic Guidance Panel Terms of Reference, which are available on the pCODR website (www.cadth.ca/pcodr). Final selection of the pool of Economic Guidance Panel members was made by the pERC Chair in consultation with the pCODR Executive Director. The Economic Guidance Panel is editorially independent of the provincial and territorial Ministries of Health and the provincial cancer agencies.

APPENDIX A: COST COMPARISON TABLE

The comparator treatments presented in the table below have been deemed the appropriate comparators by the pCODR Clinical Guidance Panel. Comparators may be recommended (appropriate) practice, versus actual practice. Comparators are not restricted to drugs, but may be devices or procedures such as surgery or radiation. Costs of drugs are manufacturer list prices, unless otherwise specified.

Sample Table 1. Treatment regimens used in the treatment of [general indication] cancer

Regimen/ Protocol	Drug/ Comparator	Strength	Dosage Form	Average daily dose (course details and cycle duration, if applicable)	Cost per unit ($)	Average cost per day in course ($)	Average cost per course ($)
Drug Under Review	Drug Under Review						
Comparator Regimen 1	Drug 1						
	Drug 2						
	Drug 3						
					Total Regimen Costs		
Comparator Regimen 2	Drug 1						
	Drug 2						
					Total Regimen Costs		

Foot Notes:

Sample Table 2. Single agents used in the treatment of [general indication] cancer

Drug/ Comparator	Strength	Dosage Form	Average daily dose (course details and cycle duration, if applicable)	Cost per unit ($)	Average cost per day in course ($)	Average cost per course ($)#
Drug Under Review						
Comparator 1						
Comparator 2						
Comparator 3						

Foot Notes:

REFERENCES

[Insert text here]